Topic 4: Strategy & Human Resource Management Topic 4: Strategy & Human Resource Topic 4: Strategy & Human Resource Management Topic 4: Strategy & Human Resource Topic 4: Strategy &amp

************* for Pediatric Clients with **** **************** ************* ************** * **************** ** **************************** *** ********* ******* **** **** ************************** patients are *** ****** from ***** depressive ******** *** ******* comorbidities **** ******* **** **** **** ** **** world *** * ***** **** *** ******* ************* ****** not overlook ********* **** condition ********** ******** and ****** *** ******* ********* ** Maughan Collishaw & ********** ****** ********* **** ********* ***** depressive ********* ***** occur at * rate ** 10-17 percentagein *** broad ********** *** ********* ** MDD ** **** ** * higher ***** ********* in ******* more than males Other ********** ************** have ********* *** ** children ** * principle ****** *** *********** in ********* *** ****** ** young ****** **** 2013) ************ there ** * ********* ** depression ** ***** **** ******** ********* ** * ****** go ******* ************ milestones Moreover ** ***** persons **** *** mental health ********** lack proper management *************** and psychologically the illnesses *** become * ********** ****** ******* **** ***** ******** ****** ****** **** reported **** only ********* ** these ******** **** ****** ****** ******** have ********** ******** from ******* clinicians *** ***** 8 ******* children *** ** at ***** *** ************ ************** ******** ** MDD seen ** ******** may ****** **** ** the **** observed ** ****** **** as decrease *** ********** ** rapid eye ******** ***** ***** ******** ******** production during depression cycles and *** genetic **** factor **** ***** ***** ********** *** youths include ********* childhood ************ ********* **** ******** *** changes ** the frontal ********* ** *** ****** and ******** ******* ** *** brain 9(Rao ***** Treatments **** as *** ******** ** ********** *** **** ** ********* is ** ******** *** signsof the ******* ******** ****** **** ******** ** *** aspects ** ********** **** ********** **** ** ******** ** ** ************* * complete assessment co-morbidities **** mental ****** history ************* ********* and *************** ************* ****** ** **** ** *** ******* purpose of this ***** is ** ******* *** psychiatric ********* *** its ****** on children ******** ********* *********** explore diagnostic tools ********* *********** **** ** antidepressants *** ponder ** ********** *** ******* ********* that *** ************ ** *** patient ***** ****** ******* *** ********** ******* ******** **** *** have reported ******** ** feeling ********* to the ** ****** ********* **** *** patient’s ******* *** said **** *** ****** *** ********** **** peersMom *** observed decrease ******** *** ********* ****** ** ********** ** ** ********** ***** ** ********** ******** **** ************ ********** tests were ******* ****** parametersand the ******* was referred ** the ***** ************ *** psychiatric ********** ****** health **** ***** ***** **** the ****** *** alert *** ******** ** ** *** * good ********* The ****** ******** ***** ********* **** ******* ****** ** ****** ************** ** denies ****** ** ******** hallucination and ** delusional ** ******** thought process ******** Age *********** awareness ******** and ************* ***** ** ****** ******* ******** ******** but *** had thoughts of ***** **** *** ********** **** ** Children's ********** ****** Scale ********* ******** ** ************* ** *********** ******************* 1What options were listed *** *** ******* listed **** Sertraline **** ** ***** ***** ***** ** mg ** mouth ***** *** Wellbutrin ** ** by mouth ************ option *** you ******* I ***** ********** ** mg ** ***** ******** *** you ****** **** ******* ********* ** Magellan Health ****** studies **** ***** that Sertraline ** *********** *** ******** depression ** young ******** ******** ** ******** “(SSRIs) **** * ********** **** response **** *** – 70%)” **** the ****** ** * ***** ****** didn’t you ****** *** ***** *** options? ******** ****** ****** **** ********* the ********* of ***** ***** as *************** *** ******** ******* **** 18 and *** **** age limitations *** ********** ************ ********** ** associated **** **** ***** *** ******** *** ******** ********* *** **** goal ** *************** initial **** ** ******* ** *** reduction ** symptoms ******* ********** to current ******** *** outcome **** you ********* No “Client returns ** theclinic in **** weeks ** change in ********** ******** ** all” * expected * ******* placebo response *** the ****** reported **** ***** *** ** change ** **************** ***** ******* **** ******* *** ****** ****** *** ****** ** ** ** ***** ***** ********** 375 mg ** ***** ***** ********** ** mg ** ***** ********* ****** *** you ******* * ***** ** ******** *** ********** to ** mg ** ***** ******** did *** ****** **** ******* ********* ** Magellan ****** ****** studies have ***** **** ********** ** *********** *** treating ********** ** ***** ******** *** *** ****** *** ** ******** ** ** ** ****** ***** *** **** **** ***** *** be *** ***** *********** **** *** to **** ** *** more ******** ******** *** select the ***** *** ******** I *** *** **** ********** 375 because it ** **** ***** the *********** dose ********** *** reason *** *** ******** ****** ** ** ** mouth ***** ** ** *** ** *** current ********** **** improve ******** ** ********* ** ** and *** ****** did *** ****** anincrease in ************** *** your **** of ************* goal ** ********* ** ***** *** ********* ** ******** without ********** ** current ******** ******** *** outcome **** you ********* Why? ****** “Depressive symptoms decrease by *** *** client ** ********** ******* ** * ******* some ******** ** symptoms *** *** 50% ***************** 3What ******* **** ******* *** ******* **** ** ******** ******* **** ****** to **** ** ******** to ********** 75 mg by mouth ********* ****** *** *** ******* * ***** ** ******** ******* ******* *** *** ****** that option? ***** ****** *** mentioned **** * *** ********* in ******** after ********* **** **************** ** * “response” My ********* ** ** ******** the ******* dose is ** *** ** ***** is ******** ********* of ******** ***** ** ********* (“When treatment ** ********** results ** ********** of essentially *** symptoms” (Stahl ******** ******** *** ****** *** ***** two options? *** ****** *** not ******** *** ***** two ******* *** that *** ****** *** * *** ******** **** ******* dose without furthersymptomsWhat *** **** **** ** treatment- *** goal is *** the ****** ** ******* ** medication leading ** ***** ********* at this ***** in the therapyWas *** ******* **** *** ********* Why?Yes ** *** ******** ***** *** ******** ** **** * The goal advances **** reduction ** ***** to response ** **** **** *** ***** four weeks ** ****** *** **** *** the ***** *** remission *** ******* *** ******** ** ** on * *********** ********** after the ****************** **** ******* ***************** ****** of prescribing ********** in every part ** medical **** ** * **** standard that ****** ** ************ when ******* **** ********* ******** and their ****** *** **** ******** ** *** ******** ******* *** how ** ** ************ to *** ***** and parents *** ********** ** this *********** need ** ***** before ********** **** ************** **** ** ************** ***** ******** *** ************ ******** ** ** ************* ****** ***** ** the ********** **** ******** **** are ******* than ** are ******* not **** to consent to ************ ***** parameters ** ****** ** consent ********** ****** ** countries “They ****** give ***** permission for treatment which must come **** their ******* It ** *** ************** ** the *********** clinician ** ****** the parents ** the expected ******** and risks of *** medication” (Vitiello 2012 **** Additionally if the ********** is ** ************ ***** the ****** *** *** ***** *** *** ******* ****** have *********** on *** ***** of *** ********** ******** ** al ***** ******** ******* *** informed ******* *** ********* *** ****** *** issues of ********** and ******** by ********* *** ******* *** ******* *** ******* *** report ***** ******************** ********* 2012)In *** ***** **** was given ** *** *** of *** ******** ***** *** more ******** ******* to ******** ********* *** ******* ********* ** *** current ********** *** ********* ********* *** to ******** Sertraline *** four more ***** *** ** *** “response”Another ************** ** to ******** the **** ** Sertralinebecauseby adding ******** quantities ** *** **** **** ** *********** ***** *************** ** ******** ******** the **** ** **** ** not ** ****** ** **** junction(Laureate ********* ******************************* ********* (2016e) **** study An ******* ******** Child ********* **** ********** ************* ***** ***** ********* ***************** ****** *** ****** *********** *** ** ************ ***** ** ******** and adolescents: * clinical ********* ********* **** https://wwwmagellanhealthcom/media/445492/magellan-psychotropicdrugs- ***************** * Collishaw S ***** ********** A ****** ********** ** ********* *** *********** Journal ** the ******** ******* ** ***** and ********** Psychiatry ***** 35–40 Rao * ****** ********** ** pediatric ******************** *** ************ ****** *** *********************************** K A *********** * * Galinkin J L ***** * * ******* T * **** I M & *** *** ***** * * ****** ********* *** ** ***** in childrenPediatrics133(3) 563-567Poznanski * *********** * (1996) ***** ********** Rating Scale--Revised Los Angeles *** ******* ************* ************* * * *************** essential psychopharmacology: *************** ***** *** ********* applications **** *** *** York NY: ********* ********** ************* B ****** Principles ** ***** psychotropic ********** ** children *** *********** ** *** ** (ed) ******* ********** of ***** *** ********** ****** Health ******* International *********** *** ***** and ********** ********** and Allied *********** ********* **** ******************************************